Alnylam Pharmaceuticals, Inc. ALNY NASDAQ

Alnylam Pharmaceuticals, Inc. (ALNY) has shown exceptional revenue growth over the past 3 years, expanding from $1.0B to $3.7B (average +54.8%/yr). Net income reached $314M, reflecting exceptional earnings expansion at +103.6%/yr on average. The net profit margin is 8.4%, which is moderate. the company was profitable in 1 out of the last 4 years tracked. The gross margin is 81.8% (high), with a -1.9pp trend over the period. With a $45B market cap and MOAT composite score of 76/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (100/100, Pass) — proving strong growth momentum
• PAST (25/100, Fail) — the company has frequently reported losses. Looking at the full 24-year history, the company was profitable in 1 of 24 years — a mixed long-term record
• INCOME (45/100, Partial) — the company is profitable but margin is below 15%
• MOAT (76/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 60/100 with 3/7 criteria passed.